Research Training in Pediatric Non-Malignant Hematology

这项新的T32培训补助金解决了培训医生科学家和临床医生的关键需求。 儿科非恶性血液学研究者。血液学研究-尤其是儿科- 阐明了许多遗传，细胞和分子机制的疾病过程，以及 作为基本的细胞功能，如细胞分化和基因调控。然而，尽管许多 在过去的几十年里，血液学的科学和临床进步， 自2002年以来，NIH的血液学相关研究一直在稳步下降。血液学培训计划 (HTP)在这个T32的支持下，将为博士后MD提供严格的基础/转化研究培训， MD/PhD和PhD研究员，在28名教师导师的指导下，由2570万美元的校外资助 资金（联邦来源17.3美元）。在埃默里大学，建立了镰状细胞的研究项目， 疾病、止血和血栓形成、造血和干细胞生物学、基因治疗和红细胞 生理学和输血医学是儿科血液学中最大的临床项目 在该国，为儿童医院的临床和转化研究提供了巨大的患者数量。 亚特兰大的医疗保健与格鲁吉亚理工学院和莫尔豪斯学院的合作伙伴关系 医学拓宽了教师导师库。每个学员将有一个实验室研究导师和一个临床 共同指导促进与儿科血液学相关的基础或转化研究。高级导师结对 从11名年轻教师中挑选初级导师，将扩大未来导师的供应。 整合到非常成功的儿科血液学/肿瘤学/骨髓移植（BMT） Aflac癌症和血液疾病中心的奖学金计划，新的HTP将接纳2名研究员 为期两年的支持，培养5-7名MD研究员和3-5名博士博士后研究员超过5年。候选人 将在奖学金培训计划和相关实验室中担任MD、MD/PhD和PhD研究员， 以及根据其先前的培训和研究成就选择的外部候选人， 学术潜力，并致力于非恶性血液学研究。除了严格的 实验室研究培训，受训人员将参加一个关于进行伦理研究的课程， 职业发展研讨会，赠款写作和学术技能培训，研究会议，期刊俱乐部， 和奖学金项目研究静修。将为每个受训者制定个人培训计划， 多学科奖学金监督委员会将监测进展情况。学员将展示他们的 在国家会议上工作，编写职业发展（K类）奖的申请书。HTP将采取 埃默里大学广泛的研究资源的优势，包括正式的课程工作和学位 通过埃默里大学的CTSA计划提供的临床和转化研究计划。设立这一 该计划将使我们能够培养下一代儿科非恶性血液学的学术领袖。

This new T32 training grant addresses the crucial need for programs to train physician scientists and clinical investigators in pediatric non-malignant hematology. Research in hematology – particularly in pediatrics – has elucidated many of the genetic, cellular and molecular mechanisms underlying disease processes, as well as fundamental cellular functions such as cell differentiation and gene regulation. Yet despite the many scientific and clinical advances in hematology over the past decades, the number of investigators funded by NIH for hematology related research has steadily declined since 2002. The Hematology Training Program (HTP) supported by this T32 will offer rigorous training in basic/translational research to postdoctoral MD, MD/PhD and PhD fellows, under the mentorship of 28 faculty mentors supported by $25.7 M in extramural funding ($17.3 from Federal sources). At Emory University, established research programs in sickle cell disease, hemostasis and thrombosis, hematopoiesis and stem cell biology, gene therapy, and red cell physiology and transfusion medicine are embedded in the largest clinical program in pediatric hematology in the country, providing huge patient volumes for clinical and translational research within Children's Healthcare of Atlanta. Partnerships with the Georgia Institute of Technology and Morehouse School of Medicine broaden the faculty mentor pool. Each trainee will have a laboratory research Mentor and a clinical Co-mentor to foster basic or translational research relevant to pediatric hematology. Pairing of senior mentors with junior mentors from a pool of 11 young faculty members will expand the supply of future mentors. Integrated into the highly successful Pediatric Hematology/Oncology/Bone Marrow Transplant (BMT) Fellowship Program of the Aflac Cancer and Blood Disorders Center, the new HTP will admit 2 fellows each year for 2 years of support, training 5-7 MD fellows and 3-5 PhD postdoctoral fellows over 5 years. Candidates will be MD, MD/PhD and PhD fellows within the Fellowship Training Program and associated laboratories, as well as external candidates chosen on the basis of their prior training and research accomplishments, academic potential, and commitment to research in non-malignant hematology. In addition to rigorous laboratory research training, trainees will participate in a course in conduct of ethical research, departmental career development seminars, grant writing and academic skills training, research conferences, journal clubs, and fellowship program research retreats. Individual Training Plans will be developed for each trainee and progress will be monitored by a multidisciplinary scholarship oversight committees. Trainees will present their work at national meetings and develop applications for career development (K-type) awards. The HTP will take advantage of the extensive research resources of Emory University, including formal course work and degree programs in clinical and translational research available through Emory's CTSA program. Establishment of this program will allow us to train the next generation of academic leaders in pediatric non-malignant hematology.